Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04420754 · ClinicalTrials.gov registry record · Phase 1

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

A Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer, sponsored by AffyImmune Therapeutics.

Active
Registry status
Phase 1
Development phase
70
Enrollment target
4
Study locations

NCT04420754 is a Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer that is active but no longer recruiting, run by AffyImmune Therapeutics. The registered enrollment target is 70 participants, above the 15-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (367% higher). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04420754, a Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by AffyImmune Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
70 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.

Conditions Studied

Anaplastic Thyroid Cancer Relapsed/Refractory Poorly Differentiated Thyroid Cancer

Interventions

  • BIOLOGICAL AIC100 CAR T Cells

Study Locations (4)

California

  • City of Hope National Medical Center, City of Hope Medical Center - Duarte

Illinois

  • Northwestern Memorial Hospital - Chicago

New York

  • Weill Cornell Medical College - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2020-09-28
Est. Completion 2030-08-04
Phase Phase 1

Sponsor

AffyImmune Therapeutics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04420754

The ClinicalTrials.gov registry entry for NCT04420754 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 15-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (367% higher). The listed sponsor is AffyImmune Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anaplastic Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which AIC100 CAR T Cells is the first listed.

NCT04420754 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT04420754 about?

NCT04420754 is a clinical study titled "Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer". The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.

What is the current status of trial NCT04420754?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-09-28. Estimated completion is 2030-08-04.

What conditions does trial NCT04420754 study?

This clinical trial studies the following conditions: Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer.

What interventions are being tested in trial NCT04420754?

The interventions under investigation include: AIC100 CAR T Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT04420754?

This trial is sponsored by AffyImmune Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04420754 being conducted?

This trial has 4 study locations across California, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anaplastic Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anaplastic Thyroid Cancer

All registered trials for this condition

Relapsed/Refractory Poorly Differentiated Thyroid Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.